57th ASH Annual Meeting and Exposition (December 5-8, 2015): 635. Myeloproliferative Syndromes: Basic Science II

Myeloproliferative Syndromes: Basic Science Oral and Poster Abstracts
Oral

W331, Level 3 (Orange County Convention Center)

Moderators:

Angela G Fleischman, MD PhD, University of California, Irvine and Stephen Oh, MD PhD, Washington University School of Medicine

Disclosures:

Oh: Incyte: Membership on an entity’s Board of Directors or advisory committees ; CTI Biopharma: Membership on an entity’s Board of Directors or advisory committees .

10:30 AM

601

Lysine-Specific Histone Demethylase, LSD1, (KDM1A) As a Novel Therapeutic Target in Myeloproliferative Neoplasms

Maria Kleppe, PhD¹, Kaitlyn Shank, BS¹^*, Papalexi Efthymia, BS²^*, Hugh Riehnhoff, MD³^* and Ross L. Levine, MD^4,5

¹Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
²Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
³Imago, San Carlos, CA
⁴Memorial Sloan Kettering Cancer Center, New York, NY
⁵Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

10:45 AM

602

NF Kappa B Signaling Hyperactivation in Myelofibrosis and Secondary Acute Myeloid Leukemia

Daniel A.C. Fisher, PhD¹, Elizabeth K. Engle, PhD¹, Olga Malkova, PhD²^*, Mary C. Fulbright¹^*, Amy Zhou, MD¹ and Stephen Oh, MD PhD¹

¹Division of Hematology, Washington University School of Medicine, St. Louis, MO
²Center For Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO

11:00 AM

603

Preclinical Efficacy of TGF-Beta Receptor I Kinase Inhibitor, Galunisertib, in Myelofibrosis

Lanzhu Yue, PhD^1,2, Matthias Bartenstein³, Wanke Zhao⁴^*, Wan-Ting Ho⁴^*, Ling Zhang, MD⁵, Franck Rapaport, PhD⁶^*, Ross L. Levine, MD⁷, Zonghong Shao², Zhizhuang Joe Zhao, PhD⁴, Amit Verma³ and Pearlie K Epling-Burnette, PhD¹

¹Department of Immunology, Moffitt Cancer Center and Research Institute, Tampa, FL
²Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China
³Department of Medicine-Oncology, Albert Einstein College of Medicine, Bronx, NY
⁴Pathology, Oklahoma University Health Sciences Center, Oklahoma City, OK
⁵Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
⁶Leukemia Center, Memorial Sloan Kettering Cancer Center, New York City, NY
⁷Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

11:15 AM

604

Mesenchymal Cell Associated Fibrosis in Experimental mpl^W515L Mouse Model of Myelofibrosis

Lanzhu Yue, PhD^1,2, Ying Han, MD³^*, Ling Zhang, MD⁴, Sheng Wei, MD², Xiubao Ren, M.D³^*, Zonghong Shao¹ and Pearlie K Epling-Burnette, PhD²

¹Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China
²Department of Immunology, Moffitt Cancer Center and Research Institute, Tampa, FL
³Biotherapy Department, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
⁴Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

11:30 AM

605

TGFb1 Antagonist Inhibits Fibrosis in a Murine Model of Myelofibrosis

Rajasekhar NVS Suragani, PhD¹, Pedro A. Martinez, PhD², Sharon M Cawley, PhD³^*, Robert Li⁴^*, Robert Scott Pearsall, PhD⁴^* and Ravindra Kumar, PhD⁵^*

¹Preclinical Pharmacology, Acceleron Pharma, Cambridge, MA
²PreClinical Pharmacology, Acceleron Pharma Inc, Cambridge, MA
³Cell Biology, Acceleron Pharma Inc, Cambridge, MA
⁴Preclinical Pharmacology, Acceleron Pharma Inc, Cambridge, MA
⁵Biology, Acceleron Pharma, Cambridge, MA

11:45 AM

606

Whole Exome Sequencing Identifies Novel MPL and JAK2 Mutations in Triple Negative Myeloproliferative Neoplasms

Jelena D Milosevic Feenstra, PhD¹^*, Harini Nivarthi, PhD¹^*, Heinz Gisslinger, MD², Emilie Leroy^3,4^*, Elisa Rumi, MD⁵^*, Ilyas Chachoua^3,4^*, Klaudia Bagienski¹^*, Blanka Kubesova, MSc^1,6^*, Daniela Pietra, PhD⁵^*, Bettina Gisslinger²^*, Roland Jäger, PhD¹^*, Doris Chen, PhD¹^*, Tiina Berg, B.Sc.¹^*, Martin Schalling, MSc²^*, Michael Schuster, PhD¹^*, Christoph Bock, PhD¹^*, Stefan N. Constantinescu, MD, PhD^3,4, Mario Cazzola, MD^5,7 and Robert Kralovics, PhD^1,2

¹CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
²Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria
³Ludwig Institute for Cancer Research, Brussels, Belgium
⁴de Duve Institute, Université catholique de Louvain, Brussels, Belgium
⁵Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
⁶Center of Molecular Biology and Gene Therapy, Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and medical Faculty MU, Brno, Czech Republic
⁷Department of Molecular Medicine, University of Pavia, Pavia, Italy

See more of: Myeloproliferative Syndromes: Basic Science
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

635.O2.6 635. Myeloproliferative Syndromes: Basic Science II